Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™
Portfolio Pulse from
Samsung Bioepis and Biogen have received European Commission approval for their aflibercept biosimilar, OPUVIZ™, marking a significant milestone in their collaboration.
November 18, 2024 | 12:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biogen, in collaboration with Samsung Bioepis, has received European Commission approval for OPUVIZ™, a biosimilar to Eylea. This approval could enhance Biogen's product portfolio and market presence in Europe.
The approval of OPUVIZ™ by the European Commission is a positive development for Biogen, as it expands their product offerings in the biosimilar market. This could lead to increased revenue opportunities in Europe, positively impacting their stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80